bioRxiv · 10.64898/2026.01.05.697065
Lenacapavir allosterically remodels the HIV-1 capsid
Abstract
Lenacapavir (LEN) is a highly potent, long-acting HIV-1 capsid inhibitor that holds exceptional promise for pre-exposure prophylaxis. LEN causes the mature viral capsid to rupture and lose integrity, but the underlying mechanism has been unclear. Here, we show that LEN is an allosteric modulator of HIV-1 capsid structure that breaks the capsids fullerene cone architecture in two steps: loss of high-curvature declinations occurs early, followed by failure of the capsid body. At the molecular level, LEN alters the non-covalent bonding interactions between capsid subunits and reduces local lattice curvature. LEN also alters the material properties of the capsid, by increasing brittleness. These results provide molecular rationales for how LEN remodels HIV-1 capsid structure and impairs the replication capacity of the virus.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
dos Santos, N. F. B., Lewis, J. A., Hansen, M., Pereira, M. J. B., Christensen, D. E., Sundquist, W. I., Ganser-Pornillos, B. K., Pornillos, O.. 2026-01-05. Lenacapavir allosterically remodels the HIV-1 capsid. https://doi.org/10.64898/2026.01.05.697065
Cite the original work for its findings. Save a collection to share your selection of sources.